Drug Trial Radar · NCT06621251
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 8, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Trellis Bioscience LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
Conditions
- Prosthetic Joint Infections of Hip
- Prosthetic Joint Infections of Knee
Interventions
TRL1068 (calpurbatug), a human monoclonal antibodyDrug
A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
DAIRProcedure
DAIR procedure will be performed between days 15-22
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of TRL1068 in eliminating the need for an SoC 2-stage exchange arthroplastyTime frame: Day 365
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
OrthoArizona
Gilbert, Arizona
UCLA
Los Angeles, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Gulfcoast Research Institute
Sarasota, Florida
Phoenix Clinical Research
Tamarac, Florida
Sinai Hospital Baltimore
Baltimore, Maryland
New England Baptist Hospital
Boston, Massachusetts
University of Rochester
Rochester, New York
M3 Wake Research Associates
Wilmington, North Carolina
North Texas Medical Research Institute
Rockwall, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.